Back
Immuneering 10K Form
Sell
28
IMRX
Immuneering
Last Price:
1.93
Seasonality Move:
-29.24%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive IMRX News And Ratings
See the #1 stock for the next 7 days that we like better than IMRX
IMRX Financial Statistics
Sales & Book Value
Annual Sales: | $316.95K |
---|---|
Cash Flow: | $-11.56M |
Price / Cash Flow: | 0 |
Annual Sales: | $2.24 |
Price / Book: | 0.82 |
Profitability
EPS (TTM): | -1.91000 |
---|---|
Net Income (TTM): | $-56.07M |
Gross Margin: | $0 |
Return on Equity: | 0% |
Return on Assets: | 0% |
Immuneering Earnings Forecast
Key Immuneering Financial Ratios
- The Selling, General & Administrative Expenses for IMRX have been equal to 4,924.12% of Gross Profit Margin.
- The Interest Expense is 0.00% of Operating Income.
- Per Share Earnings over the last 5 years have been positive in 2 years.
Immuneering Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | IMRX |
Website: | immuneering.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
IMRX Technical Analysis vs Fundamental Analysis
Sell
28
Immuneering (IMRX)
is a Sell
Is Immuneering a Buy or a Sell?
-
Immuneering stock is rated a Sell
The current Immuneering [IMRX] share price is $1.71. The Score for IMRX is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.